Acorda Therapeutics (ACOR) Misses Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acorda Provides Financial and Pipeline Update for Third Quarter 2017
October 31, 2017 6:00 AM EDTINBRIJA (levodopa inhalation powder) NDA resubmission expected Q4 2017 Tozadenant Phase 3 efficacy data expected Q1 2018 AMPYRA® (dalfampridine) Q3 2017 net revenue of $133 million Company vigorously pursuing AMPYRA appeal
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq:ACOR) provided a financial and pipeline update for the third... More
